Having a "plan" for long-haulers is not going to move the ball forward. Current management also has a plan for long-haulers, and they're already in the driver's seat. I think the real challenge is funding the next LH trial, and current management understands that today ($1.30) isn't the time to raise funds, however tomorrow (figuratively speaking) will allow us to raise the required funds without massive dilution. NP, like him or not, has been very careful to only dilute what we need for the short term knowing the share price will soon go up after the Brazil trials are started, and we get the Nash results. That will be the time to raise funds using minimal dilution. Regardless of the 13D's plan for LH, they're still going to have the funding issue, and I don't see Patterson raising funds any faster or more efficiently than NP. NP's light years ahead of Patterson when it comes to raising funds. CytoDyn isn't a tiny kit making company.

Quote:

---

These LH trials began a month or so after ours. 13d won't get a LH trial up and running for at least another year. So this is a joke and not a funny one.

---